Association between Type 2 Diabetes Loci and Measures of Fatness Authors: Slavica Pecioska, M. Carola Zillikens, Peter Henneman, Pieter J. Snijders, Ben A. Oostra, Cornelia M. van Duijn, Yurii S. Aulchenko Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0008541 ABSTRACT Type 2 diabetes (T2D) is a metabolic disorder characterized by disturbances of carbohydrate, fat and protein metabolism and insulin resistance. The majority of T2D patients are obese and obesity by itself may be a cause of insulin resistance. Our aim was to evaluate whether the recently identified T2D risk alleles are associated with human measures of fatness as characterized with Dual Energy X-ray Absorptiometry (DEXA). Genotypes and phenotypes of approximately 3,000 participants from cross-sectional ERF study were analyzed. Nine single nucleotide polymorphisms (SNPs) in CDKN2AB , CDKAL1 , FTO , HHEX , IGF2BP2 , KCNJ11 , PPARG , SLC30A8 and TCF7L2 were genotyped. We used linear regression to study association between individual SNPs and the combined allelic risk score with body mass index (BMI), fat mass index (FMI), fat percentage (FAT), waist circumference (WC) and waist to hip ratio (WHR). Significant association was observed between rs8050136 ( FTO ) and BMI ( p  = 0.003), FMI ( p  = 0.007) and WC ( p  = 0.03); fat percentage was borderline significant ( p  = 0.053). No other SNPs alone or combined in a risk score demonstrated significant association to the measures of fatness. From the recently identified T2D risk variants only the risk variant of the FTO gene (rs8050136) showed statistically significant association with BMI, FMI, and WC. INTRODUCTION Type 2 diabetes mellitus (T2D) is a metabolic disorder characterized by disturbances of carbohydrate, fat and protein metabolism and insulin resistance [1] . The effects of T2D include long-term damage, dysfunction and failure of various organs. The global prevalence of diabetes is currently estimated as 2.8% (171 millions patients worldwide), and this figure projects to at least 4.4% (366 millions) at year 2030 [2] . The majority of T2D patients are obese and obesity by itself may be a cause of insulin resistance [3] . The rapid increase in prevalence of T2D is thought to be at least partly explained by the change in environmental factors (nutrition and life style) acting on genetically susceptible individuals, who may become obese and consequently develop insulin resistance and T2D. This hypothesis received support from the fact that several candidate genes known for T2D, such as PPARG [4] and LPIN2 [5] , are involved in the development of fat tissue, while FTO [6] gene may be involved in regulation of food intake. Up until recently only few genes were unequivocally implicated in risk of Type 2 Diabetes. In the last year, large progress has been made through the genome-wide association studies. Besides confirming the previously known T2D loci PPARG [4] , TCF7L2 [7] and KCNJ11 [8] , the GWA studies have identified new loci CDKAL1 , CDKN2A/CDKN2B , IGF2BP2 , FTO , SLC30A8 and HHEX [9] – [12] that influence the risk of T2D. A recently published meta-analysis introduced yet another 6 loci associated with T2D, JAZF1 , CDC123-CAMK1D , TSPAN8-LGR5 , THADA , ADAMTS9 and NOTCH2 [13] . We have selected polymorphisms in nine T2D genes, CDKAL1 , CDKN2A/CDKN2B , FTO , HHEX , IGF2BP2 , KCNJ11 , PPARG , SLC30A8 and TCF7L2 . Two of these genes, PPARG and KCNJ11 , are well-established candidate genes involved in T2D pathways, while the other seven were discovered in initial GWAS and therefore should explain a large fraction of T2D cases. RESULTS AND DISCUSSION Association between the polymorphisms and the measures of fatness was studied in ∼3,000 participants from The Erasmus Rucphen Family (ERF) study. The ERF study is a family based study of a recent genetically isolated population located in the South West of the Netherlands [14] . Participants that were classified as diabetic, according to the use of anti-diabetic medication (oral medication or insulin) or had fasting plasma glucose levels ≥7.0 mmol/l, were excluded from the analyses (n = 145). We have studied association of the polymorphisms to fat mass index (FMI) and to fat percentage (FAT), as assessed by Dual Energy X-ray Absorptimetry (DEXA), and to body mass index (BMI), waist circumference (WC) and waist to hip ratio (WHR). In total, 3035 participants had complete genotypic and phenotypic information and were used in analysis. In this study, at nominal p  = 0.05, we had 97% power to detect influence explaining as little as 0.5% of the trait's variation, 85% power to detect 0.3% of the trait's variation and 41% power to detect 0.01% of the trait's variation. Characteristics of the population studied are presented in Table 1 and SNPs details are presented in Table 2 . All values are means or percentages±SD. BMI = body mass index, FMI = fat mass index, FAT = fat percentage, WC = waist circumference, WHR = waist to hip ratio. * = p<0.05. Chr. = Chromosome, Risk allele for type 2 diabetes underlined. Phw = p value for hardy-weinberg. Freq. Ref. = reference frequency. In our association study each SNP was individually tested for association to each of the measures of fatness traits. There was significant association between the risk allele of the FTO gene and most of the measures of fatness traits. The significant association was observed between rs8050136 and BMI p  = 0.003, FMI p  = 0.007, WC p  = 0.03 and border line significance for FAT p  = 0.053. The results of the individual SNP analyses are presented in Table 3 . All analyses are adjusted for sex and age. BMI = body mass index, FMI = fat mass index, FAT = fat %, WC = waist circumference, WHR = waist to hip ratio. b = beta coefficient, se = standard error, p = p value, * = p<0.05. To estimate the combined effect of all risk alleles on the measure of fatness traits, we computed the risk allelic score, estimated as the number of T2D risk alleles in the genotype of an individual. The mean allelic score was 9.44 (SD = 1.88, range: 3–16). Though effects of the score on every fatness trait were positive, there was no evidence for significant association between the risk score and any of the traits. The lowest, marginally nominally significant, p -values were observed for the association of the risk allelic score with body mass index ( p  = 0.067) and waist circumstance ( p  = 0.065). Results of the analyses of the risk allelic score are presented in Table 4 . β s = coefficient for sex, β a = coefficient for age, β  = coefficient for risk allelic score, pi = p-value for intercept, ps = p = value for sex, pa = p-value for age, p = p-value for measure of fatness traits. We analyzed the data stratified by disease status (type 2 diabetes yes/no) and by sex. However, there was no evidence for statistically significant association in these sub-sets. We also performed an extreme analyzes on our data, assessing an association between the measures of fatness and selected population (10% top vs. 10% bottom levels of the population). Comparing this two extreme groups we did not see escalations from the previous results. The results of the extreme analyzes are presented in Tables S1 and S2 . Our study is among the first to assess association between recently discovered T2D loci and measures of fatness as characterized with Dual Energy X-ray Absorptiometry (DEXA). We found significant association between rs8050136 ( FTO ) and BMI ( p  = 0.003), FMI ( p  = 0.007) and WC ( p  = 0.03); fat percentage was borderline significant ( p  = 0.053). No other SNPs alone or combined in a risk score demonstrated significant association to the measures of fatness. Absence of association between T2D loci and the measures of fatness may be at least partly explained because some of these were discovered using cohorts of lean subjects. This especially concerns loci discovered in the study of Sladek et al. [9] where discovery stage was based on lean participants with young onset. Later, it was shown that SLC30A8 exhibited its effect mostly in the lean participants [15] . However, the loci such as TCF7L2 , HHEX , PPARG , FTO , KCNJ11 , CDKN2B , IGNF2BP2 , and CDKAL1 , were discovered in GWAS [10] – [13] where cases were not selected for BMI. In agreement with other studies [16] we found no association between PPARG and the measures of fatness. However, the variant of PPARG (rs1801282) shows some controversy in the associations with obesity. Even though the variant has been replicated many times as a risk one for type 2 diabetes and severe insulin resistance [4] , its effect on BMI is unclear. Some studies showed that Pro12Ala allele, associated with T2D, is associated with lower body mass index [17] , but other studies showed that the same polymorphism is not associated with childhood or adult obesity [16] . Despite this controversy, the biological role of PPARG in the fat cell differentiation and lipodistrophy is strongly proven. Cauchi et al. [15] recently suggested that the effect of genetic polymorphisms, including PPARG , which have a role in adipocyte differentiation, maturation and action, and lead to insulin resistance, might be worsened by the effect of obesity. In this study we also confirm an association between the FTO gene and measures of fatness. Even thou the FTO gene was first discovered as T2D gene in an analysis not adjusted for BMI; after adjustment for BMI the effect on T2D was abolished, confirming the effect of FTO on BMI [18] . Another gene which may be involved in fat tissue development and T2D is the LPIN2 gene [5] , which is the human homologues of mouse gene Lpin1 involved also in the human lipodistrophy. To conclude, though FTO locus provides a strong example of T2D locus with an effect on measures of fatness, in general the direct effects of T2D loci on measures of fatness are limited. TABLE: General characteristics of the population studied. Trait Women (N = 1721) Men (N = 1314) Age – years 50.33±15.95 49.97±14.93 Height – cm 161.87±6.48 174.99±7.19* Weight – kg 69.11±13.44 83.19±13.91* BMI – kg/m 2 26.38±4.87 27.15±4.13* FMI – kg/m 2 10.06±3.68 7.19±2.79* FAT % 38.64±7.58 26.71±7.13* WC-cm 81.32±11.87 93.37±11.44* WHR 0.80±0.08 0.94±0.08* TABLE: T2D susceptible alleles and genotype frequencies for the ERF participants. Locus Chr SNPs Position (bp) Alleles N Allele Freq. (n) Genotype Frequencies (n) Phw Freq. Ref. A1/A2 A1 A2 A1A1 A1A2 A2A2 IGF2BP2 3 rs4402960 186994389 T /G 2891 28.8 71.2 8.8 40.1 51.1 0.238 0.29–0.30 (833) (2058) (253) (1159) (1479) CDKN2B 9 rs10811661 22124094 T /C 2888 86.6 13.4 75.1 23 1.9 0.748 0.83–0.85 (2501) (387) (2168) 666 54 CDKAL1 6 rs7754840 20769229 C /G 2871 32.7 67.3 11.4 43.3 45.3 0.127 0.31–0.36 (993) (2115) (326) (1229) (1316) PPARG 3 rs1801282 12368125 C /G 2955 90.1 9.9 81.3 17.7 1 0.757 0.82–0.86 (2662) (293) (2402) (523) (30) SLC30A8 8 rs13266634 118253964 C /T 2934 69.2 30.8 47.4 43.6 9 0.260 0.61–0.75 (2030) (904) (1391) (1278) (265) HHEX 10 rs1111875 94452862 C /T 2940 59.2 40.8 34.9 48.4 16.7 0.939 0.52–0.64 (1740) (1200) (1028) (1423) (489) KCNJ11 11 rs5219 17366148 T /C 2935 33.6 66.4 11.4 44.4 44.2 0.804 0.46–0.47 (986) (1949) (335) (1304) (1296) TCF7L2 10 rs7903146 114748339 T /C 2916 28.5 71.5 7.8 41.3 50.9 0.467 0.18–0.26 (831) (2084) (228) (1204) (1482) FTO 16 rs8050136 52373776 A /C 2942 43.1 56.9 17.2 51.8 31.0 0.011 0.38 (1268) (1674) (505) (1524) (913) TABLE: Individual effects of T2D polymorphisms. SNP Locus Risk Alle. Freq. TRAIT BMI FMI FAT WC WHR β Se p β se p β se p β se p β se p rs13266634 C 0.69 −0.18 0.14 0.28 −0.1 0.1 0.43 −0.09 0.23 0.76 −0.13 0.34 0.68 −1.33E-03 2.07E-03 0.59 SLC30A8 rs10811661 T 0.87 −0.04 0.18 0.87 −0.02 0.14 0.92 −0.01 0.3 0.99 0.06 0.46 0.91 2.02E-03 2.78E-03 0.54 CDKN2AB rs7754840 C 0.33 0.15 0.13 0.35 0.08 0.1 0.5 0.17 0.22 0.52 0.2 0.33 0.61 −4.29E-04 2.00E-03 0.86 CDKAL1 rs4402960 T 0.29 0.17 0.14 0.29 0.07 0.1 0.56 −0.06 0.22 0.83 0.35 0.33 0.38 8.09E-04 2.05E-03 0.74 IGF2BP2 rs1111875 C 0.59 0.11 0.13 0.47 0.06 0.09 0.58 0.16 0.21 0.53 0.14 0.31 0.71 6.92E-04 1.91E-03 0.76 HHEX rs1801282 C 0.9 0.25 0.22 0.31 0.22 0.16 0.24 0.65 0.35 0.13 0.38 0.52 0.53 −8.17E-05 3.17E-03 0.98 PPARG rs5219 T 0.34 −0.04 0.13 0.81 2.1E-03 0.1 0.99 0.13 0.22 0.64 0.16 0.33 0.68 1.67E-03 1.99E-03 0.48 KCNJ11 rs7903146 T 0.28 0.1 0.14 0.56 0.08 0.1 0.5 0.28 0.23 0.33 0.39 0.34 0.34 2.32E-03 2.09E-03 0.35 TCF7L2 rs8050136 A 0.43 0.45 0.13 3.0E-03* 0.31 0.09 7.0E-03* 0.51 0.21 5.3E-02 0.79 0.32 3.0E-02* 1.02E-03 1.96E-03 0.66 FTO TABLE: Effects of the risk allelic score on traits. Traits Intercept±se Sex Age Score βs±se ps βa±se pa β±se p BMI 22.25±0.60 0.79±0.20 6.65E-05 0.06±0.01 <2E-16 0.12±0.05 0.067 FMI 7.54±0.44 −2.82±0.15 <2E-16 0.04±0.01 1.15E-12 0.08±0.04 0.086 FAT 33.75±0.98 −11.77±0.32 <2E-16 0.06±0.01 4.71E-08 0.20±0.09 0.065 WC 65.19±1.46 12.26±0.48 <2E-16 0.28±0.02 <2E-16 0.27±0.13 0.081 WHR 0.66±0.01 0.14±2.9E-03 <2E-16 2.9E-03±1.0E-04 <2E-16 8.8E-04±7.7E-04 0.336 MATERIALS AND METHODS Subjects were participants of the Erasmus Ruchpen Family (ERF) study. The Erasmus Ruchpen Family (ERF) study is a family based study of a genetically isolated population located in the South West of the Netherlands. The population was founded in the middle of the 18 th century by less than 400 people and experienced exponential growth and minimal immigration during the last decades. Currently, the population consists of more than 20,000 inhabitants scattered across eight adjacent villages. For the ERF study, with the help of genealogical records, twenty couples that had at least 6 children baptized in the community church between 1850–1900 were identified. All living descendants of these couples and their spouses were invited to participate in the study. The present study is based on ∼3,000 participants. All participants gave an informed written consent, and the Medical Ethical Committee of the Erasmus Medical Center Rotterdam, approved the study protocol. DATA COLLECTION All participants of the ERF study were invited for extensive clinical examinations at the research center. Fasting blood samples, anthropometric measurements and personal interviews were obtained with medical practitioners. For the current study measures of fatness and anthropometric measurements were used. Height and weight were measured with the participants dressed in light underclothing. Fat mass and lean mass were assessed using Dual Energy X-ray Absorptiometry (DEXA). Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ). Accordingly, FMI was calculated as fat mass divided by height squared (kg/m 2 ) and LMI as lean mass divided by height squared. GENOTYPING We genotyped the following SNPs in all participants: rs7754840 ( CDKAL1 ), rs10811661 ( CDKN2AB ), rs8050136 (FTO), rs1111875 ( HHEX ), rs4402960 ( IGF2BP2 ), 5215 ( KCNJ11 ), rs1801282 ( PPARG ), rs13266634 ( SLC30A8 ) and rs7903146 ( TCF7L2 ). The genotyping was performed using TaqMan allelic discrimination Assays-By-Design (Applied Biosystems, Foster City, CA, http://store.appliedbiosustems.com ). Genotypes were determined in 2-ng genomic DNA. Reactions were performed on the TaqMan Prism 7900HT platform. STATISTICAL ANALYSES All statistical analyses were performed using statistical package R ( www.r-project.org ). Prior to analyses a quality control was performed on all SNPs, assessing a minor allele frequency (all>0.05), call rate (all>0.94) and Hardy-Weinberg Equilibrium ( Tab. 2 ), and presence of duplicates. The association analyses were done using GenABEL package [18] for R. SNPs were individually tested for association with BMI, FMI, fat percentage, waist circumference and waist to hip ratio using the linear regression model, adjusted for sex and age. The p-values were corrected by the inflation factor using genomic control method [19] . The results were not corrected for multiple testing. To estimate the combined effect of all risk alleles, the risk allelic score was calculated as total number of risk alleles (alleles associated with increase T2D) present in the genotype of the study participant. The linear regression model, adjusted for sex and age, was applied to estimate the association of the risk allelic score on the five measures of fatness. SUPPORTING INFORMATION Individual effects of T2D polymorphisms on selected population (10% bottom vs. 10% top population). (0.16 MB DOC) Effects of the risk allelic score on traits in selected population (10% bottom vs. 10% top population). (0.06 MB DOC) REFERENCES [1] ADA 2005 Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 28 S37 S42 [2] Wild S Roglic G Green A Sicree R King H 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 1047 1053 [3] Campbell PJ Carlson MG 1993 Impact of obesity on insulin action in NIDDM. Diabetes 42 405 10 [4] Altshuler D Hirschhorn JN Klannemark M Lindgren CM Vohl MC 2000 The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 76 80 [5] Aulchenko YS Pullen J Kloosterman WP Yazdanpanah M Hofman A 2007 LPIN2 is associated with type 2 diabetes, glucose metabolism, and body composition. Diabetes 56 3020 3026 [6] Cecil JE Tavendale R Watt P Hetherington MM Palmer CN 2008 An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 359(24) 2558 66 [7] Grant SF Thorleifsson G Reynisdottir I Benediktsson R Manolescu A 2007 Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 38(3) 320 323 [8] Gloyn AL Weedon MN Owen KR Turner MJ Knight BA 2003 Large-Slace Association Studies of Variants in Genetics Encoding the Pancreatic b-Cell Katp Channel Subunits Kir6.2(KCNJ11) and SUR1(ABCC8) Confirm That the KCNJ11 E23K Variant is Associated with Type 2 Diabetes. Diabetes 52 568 572 [9] Sladek R Rocheleau G Rung J Dina C Shen L 2007 A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445 881 885 [10] Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research 2007 Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 1331 1336 [11] Scott LJ Mohlke KL Bonnycastle LL Willer CJ Li Y 2007 A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 1341 1345 [12] Zeggini E Weedon MN Lindgren CM Frayling TM Elliott KS 2007 Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 1336 1341 [13] Zeggini E Scott LJ Saxena R Voight BF Marchini JL 2008 Meta-Analyses of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 40(5) 683 645 [14] Pardo LM MacKay I Oostra B van Duijn CM Aulchenko YS 2005 The effect of Genetic Drift in a Young Genetically Isolated Population. Annals of Human Genetics 69 288 295 [15] Cauchi S Nead KT Choquet H Horber F Potoczna N 2008 The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Medical Genetics 9(1) 45 [16] Ghoussaini M Meyre D Lobbens S Charpendtier G Clement K 2005 Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Medical Genetics 6 11 [17] Deeb SS Fajas L Nemoto M Pihlajamaki J Mykkanen L 1998 A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 20 284 287 [18] Frayling TM Timpson NJ Weedon MN Zeggini E Freathy RM Lindgren CM 2007 A common Variant in the FTO Gene is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science 316 889 894 [19] Aulchenko YS Ripke S Isaacs A Duijn CM 2007 GenABEL: An R library for genome-wide association analysis. Bioinformatics 15; 23(10) 1294 1296 [20] Bacanu SA Devlin B Roeder K 2000 The power of genetic control. American Journal of Human Genetics 66 1933 1944